Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
JPMA Urges Takeda to Improve Promotion Regime over CASE-J
The Japan Pharmaceutical Manufacturers Association (JPMA) has officially found that Takeda Pharmaceutical violated the trade group’s promotion code by improperly using clinical data, and pressed the drug giant to improve its promotional practices. On March 19, the JPMA’s code committee…
To read the full story
Related Article
- Takeda Submits Plans to Improve Business Practices
July 13, 2015
- Takeda to Submit Plans to Improve Business Operations after MHLW Order
June 15, 2015
- Takeda Slapped with Business Improvement Order over CASE-J
June 12, 2015
- JPMA Reinstates Nihon Pharmaceutical Membership after 1-Year Suspension
March 25, 2014
ORGANIZATION
- JPMA to Push Govt to Scrap Market-Based Drug Price Revisions
February 20, 2026
- Pharma Group Looks to Growth Strategy under Takaichi after Election Win
February 10, 2026
- Pharma Groups Call for Faster Diagnosis and R&D for Intractable, Rare Diseases
February 9, 2026
- Generic Industry Consolidation Opens Opportunities for CMOs: Industry Chief
February 6, 2026
- FIRM Warns Conditional Approval Pricing Change Could Chill Regenerative Medicine R&D
February 3, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…